Horizon Discovery introduces single cell RNAseq-linked CRISPR screening service
05 August 2020 - 12:25AM
Business Wire
- CRISPR-based screening technology platform to address critical
gaps in target ID and validation
- Single cell RNAseq-linked pooled CRISPR screening offers
high-quality screening data and biological insight
Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the
Company", or "the Group"), a global leader in the application of
gene editing and gene modulation for cell line engineering, today
announced the addition of single cell RNAseq-linked pooled CRISPR
screening to its CRISPR screening services portfolio. The platform
offers high-quality screening data and biological insight to
address critical gaps in target identification and validation.
This launch is the result of a collaboration, announced in 2018,
to develop and apply this novel research tool to discover new
biology essential for the development of future therapeutics. The
biological insight gained from Horizon’s single cell RNAseq-linked
CRISPR screening platform could help researchers to gain further
understanding into complex biological models and speed up the time
from discovery to validation by integrating the effect of gene
editing with complex gene expression mapping.
Horizon’s pooled format screens offer researchers access to
highly robust whole-genome level analyses that yield quality data
outputs. Currently, it can be challenging to adequately multiplex
the data from these screens to evaluate complex biological
phenomena occurring in a subset of edited cells. Coupling pooled
CRISPR screening to single cell RNAseq allows the impact of
CRISPR-based gene modification to be examined on a global
transcriptomic scale at single cell resolution. This could enable
scientists to address critical gaps in target identification and
validation as they work to develop new and more effective
therapeutics.
“Pooled CRISPR-Cas9 knockout screens have become a linchpin in
drug target identification and validation. The development of our
single cell RNAseq-linked pooled CRISPR screening service provides
a substantial advance to Horizon’s screening capabilities,” said
Terry Pizzie, Chief Executive Officer, Horizon Discovery. “Our
continuing development of cutting-edge services, including CRISPR
screens in primary human immune cells, means we can offer our
customers unparalleled insights into the biology that will help to
underpin future drug and cell-based therapeutics.”
For further information about Horizon’s cell-based screening
services, please visit:
https://horizondiscovery.com/navigation/screening/functional-genomic-screening
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200804005700/en/
Zyme Communications (Trade and Regional Media) Lorna
Cuddon Tel: +44 (0)7811 996 942 Email:
lorna.cuddon@zymecommunications.com
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Horizon Discovery Group Plc (London Stock Exchange): 0 recent articles
More Horizon Discvry News Articles